FDA Establishes CBER Safety Council
The new council will strengthen postmarketing oversight of cell and gene therapies, vaccines, and blood products.
Updated on Nov. 19, 2026 in Biotech

Live Poll
Do you trust federal regulators to catch safety problems with vaccines and medicines?
The U.S. Food and Drug Administration has established the CBER Safety Council within the Center for Biologics Evaluation and Research, effective November 19, 2026. The council evolved from CBER's long-standing Safety Working Group and reports directly to the CBER Director.
Why it matters
The council was created so that post-market safety oversight of biological products runs through a dedicated, cross-functional team with clear lines of accountability. Its formal surveillance partnerships with the FDA Sentinel System, VAERS, and the CDC Vaccine Safety Datalink are intended to connect safety monitoring across federal systems.
The council's scope covers cell and gene therapies, vaccines, and blood and blood products, drawing on the Division of Pharmacovigilance, the CBER Surveillance Program, and the Division of Analytics and Benefit-Risk Assessment. Membership and operating procedures have not yet been published.
The players
U.S. Food and Drug Administration
The federal agency responsible for regulating drugs, biologics, medical devices, and food safety in the United States.
The details
The council is managed by the Senior Advisor for Postmarketing Safety and brings together senior scientific and regulatory experts from across the center. It is separate from the CBER product offices and will publish public-facing safety communications after significant safety determinations.
Timeline
November 19, 2026: CBER Safety Council establishment becomes effective.
Roadmap
The council formalizes CBER's Safety Working Group into a standing governance body with direct reporting to the CBER Director. It elevates postmarketing surveillance for cell and gene therapies, vaccines, and blood products into a structure separate from the product offices.
The council is designed to improve how safety problems with cell and gene therapies, vaccines, and blood products are identified and communicated to the public. Patients and clinicians may see more public-facing safety communications after significant safety determinations.
The takeaway
Post-market safety monitoring for biologics is being moved into a dedicated, accountable structure rather than remaining a working-group function. Readers should watch the FDA website for the council's membership and operating procedures.
Further reading
For broader context on biologics regulation, explore the Biotech section.
More information
Read the full FDA announcement establishing the CBER Safety Council on the agency's website.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Do you trust federal regulators to catch safety problems with vaccines and medicines?






